Market Cap | 18.12M | P/E | - | EPS this Y | 99.00% | Ern Qtrly Grth | - |
Income | -24.54M | Forward P/E | -0.31 | EPS next Y | - | 50D Avg Chg | -53.00% |
Sales | 42.81M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -77.00% |
Dividend | N/A | Price/Book | 1.07 | EPS next 5Y | - | 52W High Chg | -89.00% |
Recommedations | 3.00 | Quick Ratio | 2.72 | Shares Outstanding | 1.24M | 52W Low Chg | 36.00% |
Insider Own | 7.44% | ROA | -14.76% | Shares Float | 764.82K | Beta | 0.55 |
Inst Own | 38.24% | ROE | -89.76% | Shares Shorted/Prior | 12.83K/1.68K | Price | 0.22 |
Gross Margin | 2.36% | Profit Margin | -57.33% | Avg. Volume | 2,754,229 | Target Price | - |
Oper. Margin | -422.02% | Earnings Date | Aug 8 | Volume | 1,048,157 | Change | 0.45% |
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Baird | Outperform | Mar 13, 20 |
Baird | Neutral | Jul 30, 19 |
Baird | Outperform | May 14, 19 |
Cowen & Co. | Outperform | May 4, 18 |
Evercore ISI Group | Outperform | Mar 19, 18 |
Jefferies | Buy | Mar 19, 18 |
William Blair | Outperform | Jan 17, 18 |
Rodman & Renshaw | Buy | May 30, 17 |
JMP Securities | Market Outperform | Mar 9, 16 |